The Cancer Dependency Map now includes data from dozens of 3D cancer models across 10 cancer types, revealing new dependencies and offering a more comprehensive resource for cancer research.

Cancer Dependency Map now includes next-generation 3D cancer models

Broad scientists expand the DepMap by adding cancer organoids and demonstrate the models’ potential to fuel new discoveries.

broad.io

This Thursday, August 6, at 6PM ET, join us in Cambridge, MA (or online) for a Broad Discovery Series talk with @jbuenrostro.bsky.social: Uncovering Adversity's "Molecular Scars." Register: broadinstitute.swoogo.com/bds2026

Evolution of botulinum neurotoxin serotype X proteases to induce inflammatory cell death in cancer cells - @broadinstitute.org @hhmi-science.bsky.social www.nature.com/articles/s41...

Evolution of botulinum neurotoxin serotype X proteases to induce inflammatory cell death in cancer cells - Nature Biotechnology

Directed evolution of proteases induces targeted, multipathway lytic cell death in cancer cells.

nature.com

New work with Ben Medoff's lab, online now! ADAMTS14 regulates YAP-driven fibroblast activation in IPF. We define an ADAMTS14–collagen V–focal adhesion pathway that contributes to $fibrosis, highlighting ADAMTS14 as a potential therapeutic target. doi.org/10.1093/ajrc...

ADAMTS14 is a Novel Modulator of Fibroblast Mechanoactivation in Pulmonary Fibrosis

AbstractRationale. Yes-associated protein (YAP)-mediated fibroblast mechanoactivation is an important driver of fibrosis in idiopathic pulmonary fibrosis (

doi.org

We're thrilled to announce the Center for Therapeutic Genetics (CTG) — a new collaboration between Broad, Boston Children’s Hospital, and Jackson Laboratory to develop genetic medicines for rare and ultra-rare diseases. (1/3)

Broad Institute, Boston Children’s Hospital, and The Jackson Laboratory launch the Center for Therapeutic Genetics, a non-profit effort to develop genetic medicines for rare and ultra-rare diseases

The new collaboration aims to develop precision medicines, including base and prime editing, to treat patients with rare diseases, using infrastructure and repeatable practices the center will share w...

broad.io

Thank you Broad Institute of MIT and Harvard for this profile. The last 2 years have been an extraordinary moment of creativity and inspiration. If you’re interested in joining us, PM me! We’re building new methods, models and ML tools - we’re recruiting at all levels!

Broad Institute@broadinstitute.org · 3w ago

Shaped by a tumultuous childhood, Broad researcher and epigenomic tool-maker @jbuenrostro.bsky.social pivots to studying the biology of stress and adversity and finding new ways to boost resilience.

Shaped by a tumultuous childhood, Broad researcher and epigenomic tool-maker @jbuenrostro.bsky.social pivots to studying the biology of stress and adversity and finding new ways to boost resilience.

A bioengineer shifts his career to explore how life experiences change the body

Shaped by a tumultuous childhood, Jason Buenrostro pivots from technology development to studying the biology of stress and adversity and finding new ways to boost resilience.

broad.io

Join us on Thursday, August 6, at 6PM ET in Cambridge, MA (or online) for a Broad Discovery Series talk with @jbuenrostro.bsky.social: Uncovering Adversity's "Molecular Scars." Register: broadinstitute.swoogo.com/bds2026

We're thrilled to announce that, along with @broadinstitute.org, @bostonchildrens.bsky.social, RARE Hope and partners, JAX was selected for ARPA-H THRIVE Award to advance gene editing platform for pediatric epilepsies and rare CNS diseases. 🧪🧬🧠

The Jackson Laboratory, with the Broad Institute and partners, selected for ARPA-H THRIVE Award to advance gene editing platform for pediatric epilepsies and rare CNS diseases

Pediatric Epilepsies & Rare CNS Gene Editing Platform (PERC) accelerates the development of precision genetic medicines for severe childhood neurologic disease.

jax.org

We're thrilled to announce that a Broad-led consortium of 12 organizations has been selected to receive funding from @arpa-h.bsky.social under its THRIVE program to launch the Pediatric Epilepsies and Rare CNS (PERC) Gene Editing Platform. broad.io/ARPA-H (1/5)

Broad-led consortium receives ARPA-H award to advance gene editing for rare pediatric epilepsy

Twelve organizations spanning gene editing science, clinical medicine, manufacturing, regulatory strategy, and patient advocacy aim to deliver first-in-human trial within three years. div.hero-section...

broad.io

So excited to see this published! This method was a long time in the making and is now being widely used to balance scale with depth, especially for participants where unbiased sequencing approaches are so much more useful than arrays

Broad Institute@broadinstitute.org · 4w ago

Broad scientists developed the Blended Genome Exome (BGE) sequencing method, which delivers high-quality, unbiased data at a lower cost than existing gold-standard methods and makes large-scale genetic studies more feasible. @genetisaur.bsky.social

Broad scientists developed the Blended Genome Exome (BGE) sequencing method, which delivers high-quality, unbiased data at a lower cost than existing gold-standard methods and makes large-scale genetic studies more feasible. @genetisaur.bsky.social

Low-cost genome sequencing approach is powering genetics research on mental illness and many other studies

The Blended Genome Exome approach delivers high-quality, unbiased genetic data at a quarter of the cost of the leading sequencing method.

broad.io

New research in Nature Methods from Project Ex Vivo shows AI models learn more from diverse cell states than from scaled datasets alone, a finding that could reshape how therapies are matched to patients. msft.it/6013vgE8l

The 2026 Richard N. Merkin Prize in Biomedical Technology honors Graeme Clark, Erwin Hochmair, Ingeborg Hochmair, Michael Merzenich, and Blake Wilson for developing the modern cochlear implant — a device used by more than 1 million people worldwide.

2026 Merkin Prize in Biomedical Technology awarded to pioneers of the modern cochlear implant

The $400,000 prize honors five researchers who developed the first medical device to generate a human sense through a direct neural interface, a groundbreaking tool used by more than one million peopl...

broad.io

In three new studies, the David Liu lab has optimized key prime editing components (guide pegRNA motifs, reverse transcriptase stability, and delivery via lipid nanoparticles), addressing key bottlenecks that previously impeded its use in animals and human patients.

Scientists improve nearly every aspect of prime editing, moving it closer to treating more genetic diseases

The advances in editing efficiency and delivery are important steps toward in vivo therapeutic prime editing.

broadinstitute.org

Won-Seok Lee @broadinstitute.org, receives the 2026 Nancy S. Wexler Young Investigator Prize, which is awarded annually to an early career researcher whose work reflects the highest caliber of excellence, diligence & creative thinking. Learn more: tinyurl.com/nswprize #curehd #huntingtonsdisease

New research in @natmed.nature.com by @danafarber.bsky.social’s Dr. Suzanne George and Dr. Bradley Bernstein reveals the clinical activity of FGFR inhibition in SDH-deficient GIST. ➡️bit.ly/497QeW8 @broadinstitute.org

My May 20 (next Wednesday!) lecture at Broad: Turns out humans don't have all the answers. There is an untapped opportunity for innovation in medicine by exploring why other species are protected from diseases common in humans. Come and find out more!

Broad Institute@broadinstitute.org · 3mo ago

Join us in Cambridge, MA (or online) for a Broad Discovery Series talk, “What Animal Superpowers Can Teach Us About Our Own DNA,” on Wednesday, May 20, at 6 pm ET with @elinork.bsky.social of @darwinsark.org. Register: broadinstitute.swoogo.com/Karlsson

Join us in Cambridge, MA (or online) for a Broad Discovery Series talk, “What Animal Superpowers Can Teach Us About Our Own DNA,” on Wednesday, May 20, at 6 pm ET with @elinork.bsky.social of @darwinsark.org. Register: broadinstitute.swoogo.com/Karlsson

NHP-dGTEx V1 derived data is available for download from @GTExPortal. NHP-dGTEx V1 contains 421 Macaque samples (372 RNA-seq and 49 WGS) from 50 subjects and 333 Marmoset samples (314 RNA-seq and 19 WGS) from 20 subjects. bit.ly/4lV8tmI

dGTEx V1 open access data is now available for download from @GTExPortal. dGTEx V1 contains 379 samples from 40 subjects. bit.ly/4rHwa3A #rnaseq

Broad researchers used their single-molecule tracking technology to reveal unexpected patterns of dimerization among EGFR family receptors, shedding light on their role in cancer. Learn more: broad.io/Peng-EGFR

Other mammals have so many abilities that we don't, but which could teach us a lot about health and disease. Join us for what promises to be a talk filled to the brim with great science and super-cute animal pictures!

Broad Institute@broadinstitute.org · 3mo ago

Have you ever wondered what animal superpowers can teach us about our own DNA? Join us in Cambridge, MA (or online) for a Broad Discovery Series talk on Wednesday, May 20 at 6 pm ET with Elinor Karlsson. Register: broadinstitute.swoogo.com/Karlsson

Excited to share our paper out today in @science.org! We directed high-content, single-cell genetic screens to ask how a disordered adapter protein orchestrates the complex process of T cell activation. (1/4) www.science.org/doi/10.1126/...

Disordered protein LAT encodes relative levels of signaling pathways in T cell activation

The disordered adapter protein linker for activation of T cells (LAT) propagates T cell receptor signaling. To interrogate how LAT coordinates multiple downstream pathways, we developed a single-cell ...

science.org

Have you ever wondered what animal superpowers can teach us about our own DNA? Join us in Cambridge, MA (or online) for a Broad Discovery Series talk on Wednesday, May 20 at 6 pm ET with Elinor Karlsson. Register: broadinstitute.swoogo.com/Karlsson

A new drug candidate designed to slow the progression of prion disease is entering a phase 1 clinical trial. The trial, led by Eric Minikel, codirector of Broad’s Prion Therapeutic Science program, will evaluate a divalent small interfering RNA (siRNA) drug candidate for safety and tolerability.

Clinical trial of a prion disease drug candidate begins enrolling participants

It’s the first time the potential treatment, a small interfering RNA targeting the prion protein, is being tested in humans.

broad.io

Out now in @cp-cellhostmicrobe.bsky.social! In collaboration with Swiss clinicians, we built the largest nasal microbial gene atlas in infants w/ and w/o cystic fibrosis to date (cont.)

The Cancer Dependency Map Consortium is entering its third phase, accelerating the next generation of cancer therapies. (1/4)

Cancer Dependency Map Consortium launches Phase 3 to accelerate next-generation therapeutics

The next stage of the academic-industrial partnership aims to expand beyond cancer vulnerabilities to investigate cancer resistance, surface targets, and high-dimensional readouts.

broadinstitute.org

The recording of "Network-based rare variant association for complex diseases" by @snz20.bsky.social is now available: youtu.be/KO-6M5lXTlI. This talk is part of @broadinstitute.org's MPG Primer series. For more info, check out broad.io/MPGPrimer.

The recording of "Epigenomic profiling and AI-guided cancer diagnostics" by @sbenfatto.bsky.social is now available: youtu.be/eO4ywdRGDN4. This talk is part of @broadinstitute.org's MPG Primer series. For more info, check out broad.io/MPGPrimer.